Inhibrx, Inc. Common Stock
INBX
INBX was delisted on the 29th of May, 2024.
100 hedge funds and large institutions have $297M invested in Inhibrx, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 40 increasing their positions, 25 reducing their positions, and 14 closing their positions.
24,400% more call options, than puts
Call options by funds: $245K | Put options by funds: $1K
60% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 25
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
1% more funds holding
Funds holding: 99 → 100 (+1)
46% less capital invested
Capital invested by funds: $548M → $297M (-$251M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$15.1M |
| 2 |
Millennium Management
New York
|
+$13.9M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$10.3M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$8.68M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$4.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$25.7M |
| 2 |
State Street
Boston,
Massachusetts
|
-$15.6M |
| 3 |
TLP
Tri Locum Partners
New York
|
-$9.06M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$5.39M |
| 5 |
Morgan Stanley
New York
|
-$2.12M |
INBX Hedge Fund Activity: Q2 2022 in Review
100 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Inhibrx, Inc. Common Stock (INBX) for Q2 2022, worth a combined $297M — down 46% from $548M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new INBX positions and 14 closed out — a net gain of 4 holders — while 40 added to existing stakes and 25 trimmed.
The largest buyer was MPM BioImpact, opening a new position worth an estimated $15.1M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $25.7M sold.
- 100 institutional investors held Inhibrx, Inc. Common Stock (INBX) as of Q2 2022, up from 99 in Q1 2022.
- Funds reported $297M of Inhibrx, Inc. Common Stock stock for Q2 2022, down 46% quarter-over-quarter.
- 18 funds opened new Inhibrx, Inc. Common Stock positions in Q2 2022 and 14 closed out, a net change of +4 holders.
- The largest Inhibrx, Inc. Common Stock buyer in Q2 2022 was MPM BioImpact, an estimated $15.1M added.
- The largest Inhibrx, Inc. Common Stock seller in Q2 2022 was Adage Capital Partners, an estimated $25.7M sold.
Based on aggregated 13F filings for Q2 2022.